RALEIGH, N.C. and SHANGHAI, June 12, 2019 --  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company,.

Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced that the Independent Ethics Committees at three leading Chinese cancer hospitals (Fujian Provincial Hospital, Tongji Medical College in Huazhong University of Science and Technology, and Qilu Hospital of Shandong University) have approved Xynomic’s application to conduct pivotal Phase 3 trial using Xynomic’s abexinostat, in combination with pazopanib, in patients with renal cell carcinoma. Dr. Jun Guo, a professor and the medical director at Peking University Cancer Hospital & Institute, will be the leading principal investigator for this trial in China.

SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) --  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the dosing of the first Chinese patient in its on-going global pivotal Phase 3 trial of Xynomic’s abexinostat combined with pazopanib as a first- or second-line therapy against renal cell carcinoma (RCC) at Peking University Cancer Hospital & Institute. Dr. Jun Guo, Professor and Medical Director at Peking University Cancer Hospital & Institute, is the leading principal investigator for this trial in China.

RALEIGH, N.C. and SHANGHAI, June 06, 2019 --  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company,.

Xynomic Pharmaceuticals Holdings, Inc. (NASDAQ: XYN) announced it recently held a “pre-IND” meeting with the U.S. Food and Drug Administration for its pan-PAF inhibitor XP-102 for the treatment of cancers. Xynomic said it's on track to file this Investigational New Drug application in the second half of 2019. The FDA has addressed Xynomic's questions and provided advice on the overall clinical development plan to advance the drugs.

RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development.

RALEIGH, N.C. and SHANGHAI, Aug. 01, 2019 (GLOBE NEWSWIRE) --  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug development company, announced that it has filed an application with the U.S. Food and Drug Administration (“U.S. FDA”) seeking Fast-Track designation for its drug candidate abexinostat as a monotherapy for the treatment of relapsed or refractory follicular lymphoma (“r/r FL”). Fast-Track designation is designed to aid in the development and expedite the review of drug candidates, which show promise in treating a serious or life-threatening disease, and address an unmet medical need.

Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast-Track designation to Xynomic’s lead drug candidate abexinostat, for use as a single agent, as a fourth-line treatment of relapsed or refractory follicular lymphoma (“FL”).

Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug development company, announced that it will present at the 3rd World-China Immunotherapy & Gene Therapy Congress 2019 to be held in Beijing from August 30th to August 31st.  The presentation will report the interim data of the ongoing Phase 1b trial, being conducted at University of California, San Francisco, evaluating the safety and efficacy of Xynomic’s abexinostat, a pan-histone deacetylase (“HDAC”) inhibitor, in combination with Keytruda®, a humanized antibody in cancer immunotherapy, for the treatment of multiple solid tumors. Abexinostat is a pan HDAC inhibitor that inhibits HDACs 1, 2, 3, 6, and 10.

Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated ...

Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced that Xynomic has received approval from China’s National Medical Products Administration (“NMPA”) to start two pivotal clinical trials in China. In these two trials, Xynomic will test its lead drug candidate abexinostat (as a single agent) as a third-line treatment of diffuse large B-cell lymphoma (“DLBCL”) and as a third-line treatment of follicular lymphoma (“FL”), respectively.

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

RALEIGH, N.C. and SHANGHAI, Aug. 16, 2019 -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development.